The first phase III study of dual immunotherapy, CheckMate 227, investigated the efficacy of nivolumab plus ipilimumab compared with platinum-based chemotherapy as frontline treatment of advanced NSCLC without EGFR or ALK mutations [25]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.